Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Badger Meter Inc (BMI) vs Crispr Therapeutics AG (CRSP) Price & Performance

Badger Meter IncTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Badger Meter Inc vs Crispr Therapeutics AG — how do they compare? Badger Meter Inc trades at $130.6 (market cap $3.93B), while Crispr Therapeutics AG trades at $53.82 (market cap $5.23B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Badger Meter Inc pays a 1.18% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

BMICRSP
Market Cap
$3.93B$5.23B
Sector
TechnologyHealth
52-Week High
$193.09$76.78
52-Week Low
$113.41$44.34
Enterprise Value
$3.84B$3.65B
Dividend Yield
1.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Badger Meter Inc

Badger Meter (BMI) trades at $132.67, down 2.76% on the day, with a bearish technical signal and mixed earnings history. Key fundamentals include a P/E of 31.78, net income margin of 14.27%, and ROE of 18.48%. Recent news highlights insider buying and multiple class-action lawsuits, while cash flow trends show net outflows.

The outlook is cautious due to legal risks and earnings misses, but analyst consensus targets $155.20, implying upside. Risks include litigation and competitive pressures, while institutional interest and solid profitability offer some support.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Returns comparison

Trailing returns across standard periods

About Badger Meter Inc

Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.

Read more on BMI

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP